The Division of Neurodevelopmental-Behavioral Pediatrics provides diagnosis and clinical care for infants and children who have, or are at risk for, neurodevelopmental or developmental-behavioral problems.
Our faculty see patients at the UW Health East Clinic, and at the following Waisman Center clinics: Autism and Developmental Disabilities Clinic, Newborn Follow-Up Clinic, Feeding Team, Down Syndrome Clinic, and the Neuromotor Development Clinic.
Division faculty also provide education on neurodevelopmental disabilities through invited presentations, postgraduate programs at UW-Madison and rotations for second-year pediatric residents and neonatal fellows.
- The division continued to expand its teaching activities last year. Under the direction of Christina Iyama-Kurtycz, MD, all division members participated in training for the developmental-behavioral rotation for pediatrics residents; the Newborn Follow-Up Clinic greatly increased training time for neonatology fellows; and Janet Legare, MD, developed Bone Dysplasia Clinic training materials for colleagues and parents.
- From FY14 to FY15, visits at the expanded Newborn Follow-Up Clinic more than doubled, and overall visits at the division’s Waisman Center Clinics were 20% over projections.
- Maria Stanley, MD, participated in the UW Health adolescent MyChart workgroup to develop and implement a pilot to expand MyChart proxy access for parents and caregivers of adolescents with disabilities.
Clinical Associate Professor and Dvision Chief
Associate Professor (CHS)
Clinical Associate Professor
Goffinski A, Stanley MA, Shepherd N, Duvall N, Jenkinson SB, Davis C, Bull MJ, Roper RJ. Obstructive sleep apnea in young infants with Down syndrome evaluated in a Down syndrome specialty clinic. Am J Med Genet A. 2015 Feb;167A(2):324-30. Epub 2015 Jan 13. PubMed PMID: 25604659.
Our faculty were principal investigators and/or co-investigators on the following grants during calendar year 2015.
|Stanley, Maria A (PI)||Genentech, Inc.||A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of the Efficacy, Safety and Tolerability of RO5186582 in Adults and Adolescents with Down Syndrome|
|Stanley, Maria A (PI)||ROCHE||A Randomized, Double-Blind, Placebo-Controlled, Parallel Group 26-Week Dose-Investigating Study to Explore the Pharmacokinetics, Pharmacodynamic Effects, Efficacy, Safety and Tolerability of RO186582 in Children with Down Syndrome Aged 6-11 Years|
|Stanley, Maria (Medical Director,
Pediatric Training Coordinator) with
Harris, Anne (PI)
|HRSA||Wisconsin MCH LEND Program|